The uniQure NV (QURE) Receives $13.29 Average Target Price from Analysts

The uniQure NV (QURE) Receives $13.29 Average Target Price from Analysts

uniQure NV (NASDAQ:QURE) has earned an average recommendation of “Buy” from the nine research firms that are covering the firm. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $13.25.

Several analysts have weighed in on the stock. Chardan Capital reiterated a “buy” rating and issued a $12.00 price objective (down previously from $20.00) on shares of uniQure NV in a research note on Tuesday, November 15th. Piper Jaffray Cos. cut shares of uniQure NV from an “overweight” rating to a “neutral” rating in a research note on Tuesday, November 15th. Jefferies Group cut shares of uniQure NV from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $28.00 to $8.00 in a research note on Monday, November 21st. Zacks Investment Research upgraded shares of uniQure NV from a “sell” rating to a “buy” rating and set a $8.00 price objective for the company in a research note on Thursday, November 17th. Finally, Oppenheimer Holdings Inc. set a $17.00 price objective on shares of uniQure NV and gave the stock a “buy” rating in a research note on Sunday, December 25th.

Several institutional investors have recently modified their holdings of QURE. JPMorgan Chase & Co. boosted its position in shares of uniQure NV by 68.5% in the second quarter. JPMorgan Chase & Co. now owns 14,174 shares of the company’s stock valued at $104,000 after buying an additional 5,760 shares during the last quarter. Capital Fund Management S.A. purchased a new position in shares of uniQure NV during the third quarter valued at approximately $111,000. TFS Capital LLC boosted its position in shares of uniQure NV by 3.0% in the second quarter. TFS Capital LLC now owns 15,156 shares of the company’s stock valued at $112,000 after buying an additional 437 shares during the last quarter. ProShare Advisors LLC boosted its position in shares of uniQure NV by 9.9% in the second quarter. ProShare Advisors LLC now owns 18,479 shares of the company’s stock valued at $136,000 after buying an additional 1,666 shares during the last quarter. Finally, Quantitative Systematic Strategies LLC purchased a new position in shares of uniQure NV during the second quarter valued at approximately $165,000. Institutional investors own 28.22% of the company’s stock.

Shares of uniQure NV (NASDAQ:QURE) opened at 5.50 on Tuesday. The stock’s 50 day moving average is $5.84 and its 200 day moving average is $7.20. The company’s market capitalization is $138.25 million. uniQure NV has a 1-year low of $5.45 and a 1-year high of $19.03.

uniQure NV Company Profile

uniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease.

Related posts

Leave a Comment